Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
BioXcel Therapeutics Inc
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03910660CT.gov A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bxcl701 (this asset) | BioXcel Therapeutics Inc | P1/2 | CCC · 50 |
| Nogitecan | National Cancer Institute (NCI) | P2 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Vinorelbine Ditartrate | EpicentRx, Inc. | P2 | BB |
| Lurbinectedin | SystImmune Inc. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | EpicentRx, Inc. | P2 | BB |
| Pembrolizumab | Thomas Jefferson University | P2 | BB |
| Carboplatin | SystImmune Inc. | P3 | BB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BB |
+22 more in the Small Cell Carcinoma cohort
Other indications for Bxcl701
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroendocrine Neoplasm | — | P1/2 | CC · 46 |
| Myelodysplastic Syndrome With Excess Blasts-2 | — | P1 | CC · 43 |
| Prostate Cancer | — | P1/2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bxcl701 in Small Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bxcl701-small-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →